SCHEMBL908100

SCHEMBL908100

CC1CC(N)=NN1c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 1/20 0.53
▸ PTGS1 P23219 1/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ PRKCZ Q05513 1/20 0.49
▸ DHFR P00374 3/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ NOTUM Q6P988 3/20 0.42
▸ HTR3E A5X5Y0 1/20 0.41
▸ HTR3B O95264 1/20 0.41
▸ HTR1D P28221 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ HTR3A P46098 1/20 0.41
▸ HTR3D Q70Z44 1/20 0.41
▸ HTR3C Q8WXA8 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ MAPT P10636 4/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11191975 0.83 ALOX5 (0.50) ALOX5PTGS1PTGS2PRKCZDHFR
SCHEMBL907869 0.81 PRKCZ (0.45) ALOX5PRKCZDHFRNOTUMMEN1
SCHEMBL11188275 0.81 PRKCZ (0.56) ALOX5PTGS1PTGS2PRKCZDHFR
SCHEMBL908054 0.78 PRKCZ (0.45) ALOX5PRKCZDHFRALDH1A1HTR3E
SCHEMBL7721905 0.77 L3MBTL1 (0.40) ALOX5PRKCZALDH1A1SIGMAR1MAPT
SCHEMBL10918593 0.72 ALOX5 (0.57) ALOX5PTGS1PTGS2PRKCZDHFR
SCHEMBL7719321 0.71 PRKCZ (0.40) PTGS2PRKCZDHFRALDH1A1MAPT
Bw-755C SCHEMBL30088397 0.70 ALOX5 (1.00) ALOX5PTGS1PTGS2DHFRALDH1A1
Bw-755C SCHEMBL2573191 0.70 ALOX5 (1.00) ALOX5PTGS1PTGS2DHFRALDH1A1
SCHEMBL11059805 0.69 MEN1 (0.41) PTGS2DHFRALDH1A1MAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 — — US claimed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 — — EP claimed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 — — WO claimed
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 — — US disclosed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 — — EP disclosed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 — — WO disclosed
EP-0070376-A1 Heterocyclic substituted-amino-pyrazolines AMERICAN CYANAMID COMPANY (US) 1983-01-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases DAO, DDO, MAOA ALOX5 1140/4885PTGS1 1991/4885PTGS2 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback